Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 36 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Keyword is Osteoporosis, Postmenopausal [Clear All Filters]
(2023).
Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations..
Maturitas. 147, 19-25.
(2021).
(2020).
Association between age at menopause and fracture risk: a systematic review and meta-analysis..
Endocrine. 63(2), 213-224.
(2019). Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide..
Maturitas. 107, 7-12.
(2018). Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis..
Endocrine. 62(2), 487-489.
(2018). THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis..
Eur J Endocrinol. 179(1), R31-R45.
(2018). Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment..
Expert Opin Ther Targets. 19(3), 299-306.
(2015). Complex association between body weight and fracture risk in postmenopausal women..
Obes Rev. 16(3), 225-33.
(2015). Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers..
Metabolism. 64(10), 1291-7.
(2015). Denosumab versus zoledronic acid in patients previously treated with zoledronic acid..
Osteoporos Int. 26(10), 2521-7.
(2015).
(2014).
Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment..
Osteoporos Int. 24(7), 2127-32.
(2013). Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis..
Clin Endocrinol (Oxf). 79(4), 499-503.
(2013). Serum sclerostin levels following treatment with parathyroid hormone..
J Endocrinol Invest. 36(4), 280.
(2013). De novo autoimmune hepatitis associated with PTH(1-34) and PTH(1-84) administration for severe osteoporosis in a liver transplant patient..
Osteoporos Int. 23(9), 2387-91.
(2012). High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density..
Horm Metab Res. 44(12), 909-13.
(2012). The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass..
Clin Endocrinol (Oxf). 77(6), 816-22.
(2012).
(2012). Aromatase inhibitors in post-menopausal endometriosis..
Reprod Biol Endocrinol. 9, 90.
(2011). Breast cancer and bone mineral density: the Marburg Breast Cancer and Osteoporosis Trial (MABOT II)..
Climacteric. 14(3), 352-61.
(2011). Coincidence of severe primary hyperparathyroidism and primary hypothyroidism in a postmenopausal woman with low bone mass--initial conservative management..
J Musculoskelet Neuronal Interact. 11(1), 77-80.
(2011). Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis..
Bone. 48(5), 972-8.
(2011). No effect of rosuvastatin in the zoledronate-induced acute-phase response..
Calcif Tissue Int. 88(5), 402-8.
(2011). The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis..
Clin Endocrinol (Oxf). 72(6), 752-7.
(2010).